Therapy News and Research

RSS

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012

Nabilone shows promise in treating diabetic neuropathy

A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.

31 Oct 2012

Telephone-based tinnitus-management program shows promise

Results from a pilot study suggest that people with tinnitus benefit from a progressive management program including cognitive behavioral therapy.

30 Oct 2012

Exercise improves hip osteoarthritis function

Patients with hip osteoarthritis can achieve improvements in function and range of motion with the help of exercise therapy, regardless of whether adjunctive manual therapy is also used, study findings suggest.

30 Oct 2012

Procalcitonin good marker of bacteremia in children with central lines

High procalcitonin levels are a good indicator of bacteremia in children with a central venous catheter who present to the emergency department with fever, suggest study findings.

30 Oct 2012

Cilostazol reduces restenosis after angioplasty in critical limb ischemia

The quinolinone derivative cilostazol may be associated with reduced restenosis, reocclusion, and clinically driven target lesion revascularization 3 months after infrapopliteal angioplasty, researchers say.

30 Oct 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Intravenous catheter replacement: an interview with Claire Rickard

Peripheral intravenous catheters (“IV drips”) are small plastic tubes inserted into veins, most frequently in the hand or arm.

30 Oct 2012

Proton therapy preserves urinary and bowel function in men with prostate cancer

Two studies led by The University of Texas MD Anderson Cancer Center have found that proton therapy preserves the quality of life, specifically urinary and bowel function, in men treated with this targeted radiation modality for prostate cancer.

30 Oct 2012

Research dispels myth that sudden cardiac death happens mainly during sports

It's a tragic news story that often makes headlines - a young, healthy, fit athlete suddenly collapses and dies of cardiac arrest while playing sports.

30 Oct 2012

CINJ visiting scientist receives International - U.S. Annual Meeting Scientific Abstract Award

Songbing Qin, MD, a visiting scientist to The Cancer Institute of New Jersey, has received the International - U.S. Annual Meeting Scientific Abstract Award at the 54th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held in Boston this week.

30 Oct 2012

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery

Elderly women with early-stage breast cancer live longer with radiation therapy and surgery compared with surgery alone, researchers at the University of Maryland School of Medicine have found.

30 Oct 2012

IPSCs may be a viable source of patient-specific articular cartilage tissue

A team of Duke Medicine researchers has engineered cartilage from induced pluripotent stem cells that were successfully grown and sorted for use in tissue repair and studies into cartilage injury and osteoarthritis.

30 Oct 2012

Immigration status, language of caregivers appear to impact care of Hispanic children with cancer

Language barriers and the immigration status of caregivers appear to impact the care of Hispanic children with cancer and affect the experience of the families within the medical system, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held here Oct. 27-30, 2012.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Doxepin oral rinse relieves mouth pain from head and neck cancer treatment

An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found.

30 Oct 2012

TTP488 slows cognitive decline in patients with mild to moderate Alzheimer's

A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer's disease.

30 Oct 2012

Complementary and alternative therapy offers self-reported benefits for arthritis patients

Nearly a quarter of patients with rheumatoid arthritis and osteoarthritis used complementary and alternative therapy (CAT) to help manage their condition, according to a study in the November issue of the Journal of Clinical Nursing.

30 Oct 2012

Notable Medicare lawsuit settlement could aid patients needing skilled nursing care, other types of therapy

News outlets explain how a recent Medicare settlement could have an important impact on people who need physical, occupational and other therapies for certain disabilities and chronic conditions.

30 Oct 2012

BioRx added to Zemaira distribution network

BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Zemaira [alpha-1 proteinase inhibitor (human)]. Zemaira is indicated for chronic augmentation and maintenance therapy in individuals with alpha1-antitrypsin (AAT) deficiency and clinical evidence of emphysema.

30 Oct 2012